Apr 6, 2021
Jonathan Rigby, CEO, Revolo Biotherapeutics discusses the company's revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, with less frequent chronic dosing and without suppression of the immune system. A goal that others have not been able to reach. Revolo Bio's platform drug candidates '1805 and '1104 are in development for rheumatoid arthritis, uveitis, eosinophilic esophagitis and allergic diseases.
@RevoloBio #AutoimmuneDisease #AllergicDisease #RheumatoidArthritis #Uveitis #EosinophilicEsophagitis